[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-354115-105":59,"doc-detail-354115-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","chemoresistance-in-the-era-of-immunotherapy-challenges-and-novel-combinatorial-strategies-for-digestive-system-tumors","Chemoresistance in the era of immunotherapy - challenges and novel combinatorial strategies for digestive system tumors","","Chemoresistance in late-stage digestive system tumors drives poor outcomes and limits the effectiveness of chemotherapy, even as immunotherapy and immune checkpoint inhibitors have expanded treatment options. This review analyzes key mechanisms underlying chemoresistance, integrating cell-intrinsic drivers such as increased drug efflux and DNA repair with tumor microenvironment factors, including immune infiltration and metabolic reprogramming. Emphasis is placed on chemotherapy-induced immunogenic cell death and its dual immunomodulatory effects. It also synthesizes advances in immunochemotherapy, oncolytic viruses, cancer stem cell targeting, epigenetic modulation, and nanoparticle-based delivery approaches to support precision oncology.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/chemoresistance-in-the-era-of-immunotherapy-challenges-and-novel-combinatorial-strategies-for-digestive-system-tumors/354115/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/chemoresistance-in-the-era-of-immunotherapy-challenges-and-novel-combinatorial-strategies-for-digestive-system-tumors/354115.png","ImageObject",300,407,{"name":92,"@type":93},"Aditya","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-03","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why is chemoresistance a major problem in digestive system tumors?","Question",{"text":112,"@type":113},"Chemotherapy resistance develops persistently in advanced disease, leading to therapeutic failure and disease recurrence. This contributes substantially to poor prognosis for late-stage cases.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How does the tumor microenvironment contribute to chemoresistance and immune evasion?",{"text":117,"@type":113},"The tumor microenvironment is heterogeneous and dynamic, creating a protective sanctuary for tumor survival. Immune-suppressive elements such as M2 tumor-associated macrophages and cancer stem cells can both promote therapeutic resistance and hinder effective immune responses.",{"name":119,"@type":110,"acceptedAnswer":120},"What combination strategies does the review highlight to overcome drug resistance?",{"text":121,"@type":113},"The review synthesizes recent advances including immunochemotherapy, oncolytic viruses, targeting cancer stem cells, epigenetic modulation, and nanoparticle-based drug delivery systems. These approaches aim to enhance efficacy through synergistic mechanisms.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},354115,1791118855,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},962085564549,"https://ap-avatar.wpscdn.com/davatar_085a072bc5b1113ac321206ff7593b45","TYPE Review  \nPUBLISHED 22 April 2026  \nDOI 10.3389/fimmu.2026.1800910  \nOPEN ACCESS  \nEDITED BY  \nJunchao Xu,  \nUniversity of Pennsylvania, United States  \nREVIEWED BY  \nYang Wang,  \nChinese Academy of Medical Sciences and Peking Union Medical College, China Hongmei Dai,  \nPeking University, China  \n*CORRESPONDENCE  \nZihan Yi  \n[yizihan@kmmu.edu.cn](yizihan@kmmu.edu.cn)[ ](yizihan@kmmu.edu.cn)Wenhui Li  \n[wenhuili64@yeah.net](wenhuili64@yeah.net)[ ](wenhuili64@yeah.net)Zhengting Chen  \n[chenzhengting@kmmu.edu.cn](chenzhengting@kmmu.edu.cn)[ ](chenzhengting@kmmu.edu.cn)†These authors have contributed equally to this work  \nRECEIVED 31 January 2026  \nREVISED 25 March 2026  \nACCEPTED 08 April 2026  \nPUBLISHED 22 April 2026  \nCITATION  \nYang L, Zhou D, Cao K, Mao D, Wang C, Wei T, Deng Y, Yi Z, Li W and Chen Z (2026) Chemoresistance in the  \nera of immunotherapy: challengesand novel combinatorial strategies for digestive system tumors.  \nFront. Immunol. 17:1800910 .  \ndoi: 10.3389/fimmu.2026.1800910  \nCOPYRIGHT  \n© 2026 Yang, Zhou, Cao, Mao, Wang, Wei, Deng, Yi, Li and Chen. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.  \nChemoresistance in the era of immunotherapy: challenges and novel combinatorial strategies for digestive system tumors  \nLu Yang1,2,3†, Di Zhou 1,2,3†, Ke Cao 1,2,3†, Dan Mao 1,2,3, Chenxi Wang 1,2,3, Tao Wei 1,2,3, Yu Deng 1,2,3, Zihan Yi 4*, Wenhui Li 1* and Zhengting Chen 1*  \n1 Department of Radiation Oncology, The Third Afﬁliated Hospital of Kunming Medical University (Yunnan Cancer Hospital, Peking University Cancer Hospital Yunnan), Kunming, China, 2 Kunming Medical University, Kunming, China, 3 Key Laboratory of Cancer Research, The Third Afﬁliated Hospital of Kunming Medical University (Yunnan Cancer Hospital, Peking University Cancer Hospital Yunnan), Kunming, China, 4 Phase I Clinical Trial Ward, The Third Afﬁliated Hospital of Kunming Medical University (Yunnan Cancer Hospital, Peking University Cancer Hospital Yunnan), Kunming, China  \nThe prognosis for late-stage digestive system tumors is poor, largely due to the development of chemotherapy resistance. Although immunotherapy, particularly immune checkpoint inhibitors, has transformed the treatment landscape for some patients, strategies to further enhance the efﬁcacy of combination therapies are still lacking, and the underlying mechanisms remain incompletely understood. To systematically address these therapeutic challenges and explore potential solutions, this review delineates the key mechanisms driving chemoresistance in digestive system tumors. It encompasses both cell-intrinsic mechanisms—such as enhanced drug efﬂux and DNA repair pathways—and extrinsic factors mediated by the tumor microenvironment (TME), including immune cell inﬁltration and metabolic reprogramming. A special emphasis is placed on the dual immunomodulatory roles of chemotherapy-induced immunogenic cell death (ICD) and its remodeling impact on the immune landscape. Given the considerable heterogeneity across digestive system cancers—including gastric, colorectal, and hepatic malignancies—the review also synthesizes recent advances in innovative combination strategies. These include immunochemotherapy, oncolytic virus, targeting of cancer stem cells (CSCs), epigenetic modulation, and nanoparticle-based drug delivery systems. Ultimately, this work aims to offer a theoretical foundation and strategic directions to overcome clinical drug resistance and advance precision oncology in digestive system tumors.  \nKEYWORDS  \nchemoresistance, combination therapy, digestive system tumors, ","cbCailt2pTeTFtnN","https://ap.wps.com/l/cbCailt2pTeTFtnN","pdf",6543025,21,"English","# Introduction\n## Chemotherapy resistance and immunotherapy response limitations\n## Tumor microenvironment interplay with chemoresistance\n# Key mechanisms of chemoresistance\n## Cell-intrinsic mechanisms (drug efflux, DNA repair)\n## Tumor microenvironment-mediated immune suppression\n# Immunomodulatory role of chemotherapy-induced immunogenic cell death\n# Innovative combinatorial strategies for digestive system tumors\n## Immunochemotherapy, oncolytic virus, CSC targeting\n## Epigenetic modulation and nanoparticle-based drug delivery","[{\"question\":\"Why is chemoresistance a major problem in digestive system tumors?\",\"answer\":\"Chemotherapy resistance develops persistently in advanced disease, leading to therapeutic failure and disease recurrence. This contributes substantially to poor prognosis for late-stage cases.\"},{\"question\":\"How does the tumor microenvironment contribute to chemoresistance and immune evasion?\",\"answer\":\"The tumor microenvironment is heterogeneous and dynamic, creating a protective sanctuary for tumor survival. Immune-suppressive elements such as M2 tumor-associated macrophages and cancer stem cells can both promote therapeutic resistance and hinder effective immune responses.\"},{\"question\":\"What combination strategies does the review highlight to overcome drug resistance?\",\"answer\":\"The review synthesizes recent advances including immunochemotherapy, oncolytic viruses, targeting cancer stem cells, epigenetic modulation, and nanoparticle-based drug delivery systems. These approaches aim to enhance efficacy through synergistic mechanisms.\"}]","Chemoresistance in the era of immunotherapy - challenges and novel combinatorial strategies for digestive system tumors | PDF",1790109064,53,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/870743611b0fa0fea535efc21a5c4a1d.webp",983,1389,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1bdb7ed8490a5cf807299d0961886c91.webp",982,1388,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/48192c047951d317f2f7b5224b16c025.webp",981,1386,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3be01b922aefd316b57e70da8bd35ac1.webp",980,1385]